# Xtl Biopharmaceuticals Ltd (XTLB)

Source page: https://stoqly.net/companies/xtlb

- **Ticker:** XTLB (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001023549
- **Latest annual report:** 20-F filed 2026-06-30 (https://www.sec.gov/Archives/edgar/data/1023549/000121390026073831/ea0296095-20f_xtlbio.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $1.61 on 2026-10-30
- **Market cap:** $1.4B
- **EPS, trailing 12 months:** −$0.01
- **Revenue (FY2025):** $0.0M
- **Revenue growth:** −98.4%
- **Operating margin:** −24,114.3%
- **Net margin:** −99,557.1%
- **Return on equity:** −269.0%
- **Change in share count:** +33.2%
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/xtlb/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | — | — | — | — | — | — | — | — | 0 | 0 |
| Operating income | -3 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 |
| Net income | -3 | -1 | 4 | -1 | -3 | 0 | -1 | -2 | -1 | -7 |
| Diluted EPS (US$) | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Operating cash flow | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -1 |
| Free cash flow | -2 | — | — | -1 | -1 | — | — | — | -2 | — |
| Cash | 2 | 3 | 3 | 4 | 4 | 3 | 2 | 1 | 0 | 0 |
| Debt and leases | — | — | — | — | — | — | — | — | 0 | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.